Use of anti-CD20 therapy in follicular and marginal zone lymphoma: a review of the literature

Article Page

Abstract

The identification of the CD20 antigen in 1979 was the first step in what would become a therapeutic milestone opening the use of immunotherapy in hematological diseases. This protein is expressed on the surface of developing B cells, but not the early progenitors or mature plasma cells. In 1997, rituximab was approved by the Food and Drug Administration, and since then it has revolutionized the treatment of B-cell malignancies. It is used as a monotherapy and in combination, at induction, at relapsed, and also in maintenance. Indolent non-Hodgkin lymphomas are characterized by a long and non-aggressive course. In this group of lymphomas, rituximab represented a great therapeutic improvement, achieving lasting responses with few adverse effects. Nowadays, second-generation molecules are emerging that may have important advantages compared to rituximab, as well as biosimilars that represent an important cost-effective option.

Keywords: anti-CD20, biosimilars, immunotherapy, indolent non-Hodgkin lymphoma

Citation: Juárez-Salcedo LM, Conde-Royo D, Quiroz-Cervantes K, Dalia S. Use of anti-CD20 therapy in follicular and marginal zone lymphoma: a review of the literature. Drugs in Context 2020; 9: 2019-9-3. DOI: 10.7573/dic.2019-9-3

Contributions: L.M.J.-S. and D.C.-R. contributed equally to the preparation of this review. S.D. came up with the concept of the review. All authors worked on initial searches, drafts, review and checks of drafts and contributed to the final manuscript. All named authors meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship for this article, take responsibility for the integrity of the work as a whole, and have given their approval for this version to be published.

Disclosure and potential conflicts of interest: The authors declare that they have no conflicts of interest relevant to this manuscript. The International Committee of Medical Journal Editors (ICMJE) Potential Conflicts of Interests form for the authors is available for download at: https://www.drugsincontext.com/wp-content/uploads/2020/04/dic.2019-9-3-COI.pdf

Acknowledgements: None.

Funding declaration: There was no funding associated with the preparation of this article.

Copyright: Copyright © 2020 Juárez-Salcedo LM, Conde-Royo D, Quiroz-Cervantes K, Dalia S. Published by Drugs in Context under Creative Commons License Deed CC BY NC ND 4.0 which allows anyone to copy, distribute, and transmit the article provided it is properly attributed in the manner specified below. No commercial use without permission.

Correct attribution: Copyright © 2020 Juárez-Salcedo LM, Conde-Royo D, Quiroz-Cervantes K, Dalia S. https://doi.org/10.7573/dic.2019-9-3. Published by Drugs in Context under Creative Commons License Deed CC BY NC ND 4.0.

Article URL: https://drugsincontext.com/use-of-anti-cd20-therapy-in-follicular-and-marginal-zone-lymphoma:-a-review-of-the-literature

Correspondence: Samir Dalia, Hematology/Oncology, Mercy Clinic Oncology and Hematology, Joplin, Missouri, USA. sdalia@gmail.com

Provenance: invited; externally peer reviewed.

Submitted: 24 September 2019; Peer review comments to author: 25 November 2019; Revised manuscript received: 13 January 2020; Accepted: 27 March 2020; Publication date: 6 May 2020.

Drugs in Context is published by BioExcel Publishing Ltd. Registered office: Plaza Building, Lee High Road, London, England, SE13 5PT.

BioExcel Publishing Limited is registered in England Number 10038393. VAT GB 252 7720 07.

For all manuscript and submissions enquiries, contact the Editor-in-Chief gordon.mallarkey@bioexcelpublishing.com

For all permissions, rights and reprints, contact David Hughes david.hughes@bioexcelpublishing.com

Download free full text PDF